|
Caffeine related disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Sub-phenotype analyses targeting the alcohol, caffeine and sweetener components of beverages yielded additional loci: (i) four loci for bitter alcoholic beverages (GCKR, KLB, ADH1B and AGBL2); (ii) five loci for bitter non-alcoholic beverages (ANXA9, AHR, POR, CYP1A1/2 and CSDC2); (iii) 10 loci for coffee; six novel loci (SEC16B, TMEM18, OR8U8, AKAP6, MC4R and SPECC1L-ADORA2A); (iv) FTO for SSBs.
|
31046077 |
2019 |
|
Renal Insufficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mendelian randomization using GWAS meta-analysis data was performed to estimate the causal effect of non-alcoholic fatty liver disease (PNPLA3, LYPLAL1, NCAN, GCKR) on eGFR (N<sub>max</sub> 118,460), microalbuminuria (N<sub>max</sub> 54,116), and impaired renal function (N<sub>max</sub> 118,147).
|
31668939 |
2019 |
|
Liver diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The prevalence of possession of both PNPLA3 and GCKR variant alleles combined was significantly higher in at-risk patients with clinically significant liver disease indicated by serum PIIINP above 11 ng/mL (P = .014).
|
29493856 |
2018 |
|
Hypertensive heart and renal disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Association of common gene variants in glucokinase regulatory protein with cardiorenal disease: A systematic review and meta-analysis.
|
30352097 |
2018 |
|
Enzyme inhibition disorder
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Glucokinase regulatory protein (GKRP) binds to GCK, leading to enzyme inhibition and import into the nucleus at fasting.
|
29704611 |
2018 |
|
Metabolic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Further investigations to dissect the relationship between GCKR and FGF21, with respect to the risk of metabolic diseases, are warranted.
|
28385800 |
2017 |
|
Polycystic Ovary Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The intragenic rs1244979, rs2815752 in NEGR1 gene, and rs780094 in GCKR gene were genotyped and CNVs were determined by droplet digital polymerase chain reaction (ddPCR) in PCOS patients (n = 153) and controls without metabolic syndrome (n = 142).
|
27878529 |
2017 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
GCKR and PPP1R3B identified as genome-wide significant loci for plasma lactate: the Atherosclerosis Risk in Communities (ARIC) study.
|
26433129 |
2016 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
GCKR and PPP1R3B identified as genome-wide significant loci for plasma lactate: the Atherosclerosis Risk in Communities (ARIC) study.
|
26433129 |
2016 |
|
Hepatitis
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Common variants in GCKR enhance de novo hepatic lipogenesis in response to glucose and liver inflammation.
|
26409295 |
2016 |
|
Diabetic dyslipidaemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A Common Gene Variant in Glucokinase Regulatory Protein Interacts With Glucose Metabolism on Diabetic Dyslipidemia: the Combined CODAM and Hoorn Studies.
|
27660121 |
2016 |
|
Kidney Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Recently, genome-wide association studies (GWASs) have shown that variants in the gene encoding GKRP protect against T2DM and kidney disease but predispose to gout, nonalcoholic fatty liver disease, and dyslipidemia.
|
26432016 |
2015 |
|
Neural Tube Defects
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Combined analysis of data from the two stages showed an association between maternal AA genotype of GCKR rs780094 and increased risk for total NTDs [odds ratio, 1.73; 95% confidence interval, 1.16-2.59) and spina bifida subtype [odds ratio, 1.83; 95% confidence interval, 1.16-2.88).
|
25369983 |
2015 |
|
Spina Bifida
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Combined analysis of data from the two stages showed an association between maternal AA genotype of GCKR rs780094 and increased risk for total NTDs [odds ratio, 1.73; 95% confidence interval, 1.16-2.59) and spina bifida subtype [odds ratio, 1.83; 95% confidence interval, 1.16-2.88).
|
25369983 |
2015 |
|
Malignant neoplasm of stomach stage IV
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest IGF2BP2 and KCNQ1 polymorphisms might be independent predictors of chemotherapeutic response, while GCKR polymorphisms might be independent predictors of survival in MGC patients treated with first-line EOF chemotherapy.
|
26115082 |
2015 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
No differences in genotype distributions were found except for underrepresentation of GCKR TT homozygotes among GCK-MODY patients (10.9% in GCK-MODY vs. 17.7% in T1DM, p=0.0651).
|
24918535 |
2014 |
|
Diabetes, Autoimmune
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genetic variability of GCKR alters lipid profiles in children with monogenic and autoimmune diabetes.
|
24918535 |
2014 |
|
Fibrosis, Liver
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In patients with NAFLD, GCKR rs780094 C>T is associated with the severity of liver fibrosis and with higher serum triglyceride levels.
|
24498332 |
2014 |
|
Monogenic diabetes
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The study group included 129 children with GCK-MODY from the Polish Registry of Monogenic Diabetes and 395 with type 1 diabetes (T1DM), in whom we genotyped 2 SNPs in G6PC2 (rs560887) and GCKR (rs1260326).
|
24918535 |
2014 |
|
Hepatitis C
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
From these, we more fully evaluated the following: asparagine-linked glycosylation 10 homolog (yeast, α-1,2-glucosyltransferase); butyrylcholinesterase; dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2); glucokinase (hexokinase 4) regulator; guanylate cyclase 1, soluble, β 3; MYST histone acetyltransferase 1; protein phosphatase 3 (formerly 2B), catalytic subunit, β isoform; peroxisomal proliferator-activated receptor-γ-DBD-interacting protein 1; and solute carrier family 27 (fatty acid transporter), member 2; and demonstrated that they enabled IFNα-mediated suppression of HCV at multiple steps of its life cycle.
|
23462180 |
2013 |
|
Impaired glucose tolerance
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Induction of G6PC and GCKR manifests as hepatic glucose intolerance or insulin resistance.
|
23022226 |
2013 |
|
Severe hypoglycaemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There was no significant difference in the genotype distribution between the control group and the cases with SH for any of the investigated polymorphisms (OR and 95% confidence intervals - 0.90 (0.59-1.38) for GCKR; 1.11 (0.67-1.85) for GIPR; 0.75 (0.48-1.17) for ADCY5; 1.43 (0.95-2.15) for VPS13C; all P-values >0.05).
|
22956255 |
2013 |
|
Pancreatic carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In a multivariate-adjusted model, a significant association was observed only for rs780094 in the glucokinase regulator (GCKR) gene: odds ratios for pancreatic cancer were 1.00 for TT, 1.35 (95% CI, 0.71-2.58) for CT, and 2.14 (95% CI, 1.12-4.08) for CC genotypes (P trend = 0.01) and did not change after the adjustment for diabetes.
|
22015968 |
2012 |
|
Malignant neoplasm of pancreas
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In a multivariate-adjusted model, a significant association was observed only for rs780094 in the glucokinase regulator (GCKR) gene: odds ratios for pancreatic cancer were 1.00 for TT, 1.35 (95% CI, 0.71-2.58) for CT, and 2.14 (95% CI, 1.12-4.08) for CC genotypes (P trend = 0.01) and did not change after the adjustment for diabetes.
|
22015968 |
2012 |
|
Dysglycemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Associations of apolipoprotein A5 (APOA5), glucokinase (GCK) and glucokinase regulatory protein (GCKR) polymorphisms and lifestyle factors with the risk of dyslipidemia and dysglycemia in Japanese - a cross-sectional data from the J-MICC Study.
|
22517333 |
2012 |